Grifols (GRF SM) aims to raise USD 5bln in US IPO of biopharma business; expects to sell as much as 20% of unit

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

Russia may reinstate temporary ban on gasoline exports, IFX reports

SLB (SLB) to serve as modular design partner for Nvidia (NVDA) DSX AI Factories; SLB and NVDA will develop an AI factory for Energy with Generative AI models

Grifols (GRF SM) aims to raise USD 5bln in US IPO of biopharma business; expects to sell as much as 20% of unit

Ending the war is only possible by achieving Iran's strategic goals, according to Fars News; "Iran does not accept a ceasefire. Basically, it is not logical to enter into such a process with those who violate the agreement."

Meta Platforms (META) and eBay (EBAY) partner for new affiliate programme

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Context

Grifols' plan to raise $5 billion in an IPO for a segment of its biopharma business signals a potential consolidation move and capital generation strategy. Selling up to 20% of the unit could indicate strong investor interest and may enhance liquidity for future investments or debt reduction. Watch for implications on peer valuations and investor sentiment in the biopharma sector as this unfolds.

Related headlines

The feed had this first.

Use the Platform